Temozolomide 20 mg (Generic)

Product Overview

Temozolomide 20 mg Generic is manufactured by Cipla Limited. The active ingredient is temozolomide, an oral alkylating agent used primarily in oncology. The medication is presented in a strip that holds five capsules. Pack sizes available include five capsules, fifteen capsules, and thirty capsules, allowing patients to choose the quantity that best fits their treatment schedule. The drug is indicated for the management of brain tumors, especially high‑grade gliomas such as glioblastoma multiforme. Each strip is sealed to protect the capsules from moisture and light, ensuring stability until the moment of use.

What is Temozolomide

Temozolomide belongs to a class of compounds known as triazene derivatives. It functions as a prodrug that is converted intracellularly to an active metabolite which interferes with DNA replication. The resulting DNA lesions prevent cancer cells from repairing their genetic material, leading to cell death. The United States National Institutes of Health (NIH) recognizes temozolomide as a standard therapeutic option for certain malignant brain tumors. Because the capsule is taken by mouth, the drug can be administered in an outpatient setting, reducing the need for intravenous access.

Uses and Benefits

The primary use of temozolomide 20 mg is the treatment of newly diagnosed glioblastoma multiforme when combined with radiation therapy. It is also employed in the management of other high‑grade gliomas and occasionally in lower‑grade tumors that demonstrate aggressive behavior. Patients benefit from the oral route, which allows for convenient dosing at home and improves quality of life compared with continuous infusion regimens. Clinical studies cited by the US Food and Drug Administration (FDA) have shown that temozolomide can extend progression‑free survival and, in some cases, overall survival. The medication is also valued for its ability to cross the blood‑brain barrier efficiently, delivering therapeutic concentrations directly to tumor tissue.

How It Works

Temozolomide is a small molecule that undergoes spontaneous hydrolysis at physiological pH to form a reactive intermediate known as MTIC. This intermediate alkylates DNA at the O‑6 position of guanine, creating cross‑links that disrupt the normal pairing of nucleotides. The O‑6 methyl‑guanine lesions are recognized by the mismatch repair system, which attempts to correct them but often fails, leading to futile repair cycles and ultimately apoptosis. Because rapidly dividing tumor cells have limited capacity to repair DNA damage, they are more susceptible to the cytotoxic effects of temozolomide than most normal cells. This mechanism underlies its antineoplastic activity in brain tumors.

Dosage Guidelines

The recommended starting dose of temozolomide 20 mg is typically 75 mg per square meter of body surface area taken once daily for five consecutive days, followed by a rest period of two to three weeks before the next treatment cycle. The exact schedule may be adjusted based on the patient’s overall health, kidney function, and tolerance of side effects. Patients should take the capsules on an empty stomach, preferably one hour before or two hours after meals, and swallow them whole without crushing or chewing. It is important to adhere to the prescribing physician’s instructions and to report any missed doses promptly. For detailed dosing tables, refer to the US Food and Drug Administration prescribing information.

Side Effects

Like all chemotherapeutic agents, temozolomide can cause a range of adverse effects. The most frequently reported side effects include nausea, vomiting, fatigue, and headache. Hematologic toxicities such as neutropenia, thrombocytopenia, and anemia are also common and may necessitate regular blood monitoring. Some patients experience alopecia, although hair loss is generally less pronounced than with traditional chemotherapy. Gastrointestinal disturbances, including loss of appetite and constipation, may occur. In rare cases, patients develop severe skin reactions or neurologic symptoms that require immediate medical attention. Any unexpected symptom should be communicated to the treating oncologist.

Warnings and Precautions

Before initiating therapy, clinicians should evaluate renal function, liver enzymes, and baseline blood counts. Patients with a history of hypersensitivity to temozolomide or other nitrosourea agents should avoid use. Because the drug can be teratogenic, women of reproductive potential must use effective contraception and avoid pregnancy during treatment and for a defined period afterward. Concomitant use of other myelosuppressive medications may increase the risk of severe cytopenias. Regular laboratory tests are recommended to monitor neutrophil and platelet counts, especially during the first cycle. If severe nausea or vomiting persists, supportive care with antiemetics should be provided. For additional guidance, consult the National Institutes of Health resources.

Frequently Asked Questions

Can temozolomide be taken with other medications? Patients should inform their healthcare provider about all prescription, over‑the‑counter, and herbal products they are using. Certain anticonvulsants and antimetabolites may alter the metabolism of temozolomide and increase the risk of side effects. A medication review helps prevent harmful interactions.

What should I do if I miss a dose? If a dose is missed, the patient should not double the next dose. Instead, the missed capsule should be skipped and the regular dosing schedule resumed. It is advisable to contact the prescribing physician for guidance, especially if multiple doses are missed.

Is temozolomide safe during pregnancy? Temozolomide is classified as a Category D teratogen. Pregnant women must avoid its use, and effective contraception is required for both male and female patients of childbearing age throughout the treatment period and for a specified washout time after therapy.

How long does treatment typically continue? Treatment cycles often follow a 28‑day schedule with five consecutive days of dosing followed by a three‑week rest period. The total number of cycles is determined by the oncologist based on response, tolerance, and disease status.

Where can I find more information about this medication? Detailed prescribing information is available from the FDA and the National Institutes of Health. Patients can also refer to MedlinePlus for consumer‑friendly explanations of side effects, dosing, and storage.

Related Products

• Ciplox 750mg (Ciprofloxacin)
• Diclofenac SR 100 mg
• Reactin 50 mg (Diclofenac)
• Cromal Forte Eye Drop (Sodium Cromoglycate)
• Alendronic Acid 35 mg (Generic)
• Rizact 5 mg (Rizatriptan)
• Flunarizine 5 mg (Generic)
• Temonat Capsule (Temozolomide)
• Warf 1 mg (Warfarin)
• Warf 2 mg (Warfarin)
• Warf 3 mg (Warfarin)
• Mucinac 200 mg (Acetylcysteine)